While there are a few different strategies to build wealth through the stock market, this Footsie ETF may be the most ...
The vaccine race: it was Brexit and Bingham what won it. There were good reasons for any member of the Tory Government to ...
Britain's top brass filed into my office in No 10, bearing with them hundreds of years of collective operational experience, ...
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.
AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...
The nation’s health department has distributed 900 million free at-home COVID tests since winter 2021. It restarted the program Thursday.
The FDA has approved at-home self- or caregiver-administration of FluMist (influenza vaccine live, intranasal).
GlobalData on MSN5h
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLCTagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.
The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp. (TM), AstraZeneca ...
Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback